Evidence map›Paper›PMID 35861125›Full record

ArticleBJU international2023

The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer.

Janneke E W Walraven, Theodora M Ripping, Jorg R Oddens, Bas W G van Rhijn, Catharina A Goossens-Laan, Maarten C C M Hulshof, BlaZIB Study Group, Lambertus A Kiemeney, J A Witjes, Valery E P P Lemmens and 4 more

Abstract read
In one paragraph

Article in BJU international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Janneke E W WalravenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0001-7161-5369
Theodora M RippingDepartment of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.ORCID 0000-0002-2913-3531
Jorg R OddensDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
Bas W G van RhijnDepartment of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Catharina A Goossens-LaanDepartment of Urology, Alrijne Hospital, Leiderdorp, the Netherlands.
Maarten C C M HulshofDepartment of Radiotherapy, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, the Netherlands.
BlaZIB Study Group
Lambertus A KiemeneyRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
J A WitjesDepartment of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.
Valery E P P LemmensDepartment of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
Jacobus J M van der HoevenDepartment of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
Ingrid M E DesarDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Katja K H AbenDepartment of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
Rob H A VerhoevenDepartment of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.

Funding

KWF Kankerbestrijding KWF; IKNL 2015-7914
6 · The paper itself

Abstract

objectivesTo investigate the role of specialised genitourinary multidisciplinary team meetings (MDTMs) in decision-making and identify factors that influence the probability of receiving a treatment plan with curative intent for patients with muscle invasive bladder cancer (MIBC). PATIENTS AND

methodsData relating to patients with cT2-4aN0/X-1 M0 urothelial cell carcinoma, diagnosed between November 2017 and October 2019, were selected from the nationwide, population-based Netherlands Cancer Registry ('BlaZIB study'). Curative treatment options were defined as radical cystectomy (RC) with or without neoadjuvant chemotherapy, chemoradiation or brachytherapy. Multilevel logistic regression analyses were used to examine the association between MDTM factors and curative treatment advice and how this advice was followed.

resultsOf the 2321 patients, 2048 (88.2%) were discussed in a genitourinary MDTM. Advanced age (>80 years) and poorer World Health Organization performance status (score 1-2 vs 0) were associated with no discussion (P < 0.001). Being discussed was associated with undergoing treatment with curative intent (odds ratio [OR] 3.0, 95% confidence interval [CI] 1.9-4.9), as was the involvement of a RC hospital (OR 1.70, 95% CI 1.09-2.65). Involvement of an academic centre was associated with higher rates of bladder-sparing treatment (OR 2.05, 95% CI 1.31-3.21). Patient preference was the main reason for non-adherence to treatment advice.

conclusionsFor patients with MIBC, the probability of being discussed in a MDTM was associated with age, performance status and receiving treatment with curative intent, especially if a representative of a RC hospital was present. Future studies should focus on the impact of MDTM advice on survival data.

Indexed as

Urinary Bladder NeoplasmsAged, 80 and overCystectomyHumansNeoadjuvant TherapyNeoplasm InvasivenessPatient Care TeamUrinary Bladder#BladderCancer#blcsmcurative intent treatmentmultidisciplinary team meetingmuscle-invasive bladder cancerradical cystectomy hospitaltreatment advice#uroonc

Identifiers

PMID35861125
PMCPMC10087452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.